Cogstate Limited

Stocks

CGS

AU000000CGS8

Market Closed - Australian S.E. 07:10:14 11/09/2026 BST			5-day change	1st Jan Change
3.000 ^AUD	-0.33%		-2.28%	+32.74%

08-18	Cogstate Limited, 2026 Earnings Call, Aug 18, 2026
08-18	Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI

Transcript : Cogstate Limited - Special Call

Published on 06/10/2026 at 02:20 am BST - Modified on 06/10/2026 at 09:35 am BST

S&P Capital IQ

Presenter Speech
Rebecca Wilson (Attendees)

Hello, everyone, and welcome to today's webinar unlocking sustainable clinical trials growth, which is part of the Cogstate Investor Insight series. I'm

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Cogstate Limited

08-18	Cogstate Limited, 2026 Earnings Call, Aug 18, 2026
08-18	Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-17	Cogstate Limited Provides Revenue Guidance for the Fiscal Year 2027	CI
08-17	Cogstate Limited announces Annual dividend, payable on September 22, 2026	CI
07-08	Cogstate's June Quarter Net Sales Contracts Rises	MT
06-10	Cogstate Limited - Special Call
05-21	Cogstate Limited Announces Changes in Joint Company Secretary Positions Effective May 22, 2026	CI
04-23	Cogstate Limited Announces Board and Committee Changes	CI
04-08	Cogstate Says Nine-Month Total Sales Contracts Reach $67.1 Million, Shares Up 6%	MT
04-08	Cogstate posts 3Q26 sales contracts executed total $25.4 million	RE
02-19	Cogstate Limited, H1 2026 Earnings Call, Feb 19, 2026
02-18	Cogstate Limited Provides Revenue Guidance for the Second Half of Fiscal Year 2026	CI
02-18	Tranche Update on Cogstate Limited's Equity Buyback Plan announced on November 11, 2025.	CI
02-18	Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
01-22	Cogstate Posts Higher Fiscal H1 Revenue, Clinical Trial Contract Value; Shares Up 7%	MT